




## medmix at a glance

We design, develop, manufacture and deliver innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end markets.

Our group is organized into two business areas — Healthcare and Consumer & Industrial — and five market segments:



**Cross-functional teams and know-how transfer across our market segments to maximize synergies within the group**

All of our market segments benefit from our diversified exposure to growing end markets which are supported by long-term mega trends, such as the growing middle class, aging populations and the trend towards increased urbanization, homecare and sustainability.

### Helping people live healthier and more confident lives

Our Healthcare business area is divided into the Dental, Drug Delivery and Surgery market segments. In the Dental market segment, our customers use our mixing and delivery devices for a broad range of applications, such as prosthetics, restorations, anesthetics and aesthetics. The Drug Delivery market segment offers drug delivery devices that are used to inject fertility drugs and growth hormones and to treat niche diabetes indications, osteoporosis and rare diseases. In the Surgery market segment, our mixing and delivery devices are used to inject bone cement and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.

## Innovative, high-precision delivery

In our Consumer & Industrial business area, we operate through the Industry and Beauty market segments. In the Industry market segment, our dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways and aerospace), electronics assembly, infrastructure and DIY industries. In the Beauty market segment, our microbrushes are used for the application of color cosmetics, such as mascara and skin care, but also in non-beauty-related areas, such as cleaning devices for consumer products.

We have a strong legacy of setting industry standards through the continuous launch of innovative products in the niche business-to-business (B2B) markets in which we operate.

## Our intellectual property

In 2021, close to half our revenue was derived from products protected by approximately 900 active patents and other intellectual property (IP) rights such as trademarks and registered designs. In addition, we benefit from well-established co-development and customer-centric innovation processes, which have always had a high priority at medmix, resulting in a thorough understanding of our customers' needs and extensive design and production know-how.


We operate 13 production, logistics and distribution sites throughout the world, most of which are centered around our plastic injection molding core competencies and serve more than one market segment to satisfy the needs of our local customers in a timely and flexible manner.



## Our key figures

Our revenue increased by 30.2% (21.5% organically), back to pre-pandemic 2019 levels and closing the year with a record order backlog. We reached a profitability of 25.0% adjusted EBITDA margin. Free cash flow generation of CHF 55.6 million was an improvement of CHF 46.2 million over the previous year.

Share of revenue by market segment  
2021



- 25.4% Dental
- 8.9% Drug Delivery
- 2.8% Surgery
- 35.1% Industry
- 27.8% Beauty

## Key figures

millions of CHF	2021	2020	Change in +/-%	+/-% adjusted <sup>1)</sup>	+/-% organic <sup>2)</sup>
Revenue	457.3	351.3	30.2	30.2	21.5
Gross profit	181.2	121.1	49.7		
Operating income (EBIT)	59.9	18.1	231.2		
EBITDA	111.7	61.2	82.4		
Adjusted EBITDA	114.5	66.0	73.4		
Adjusted EBITDA margin	25.0%	18.8%			
Net income attributable to shareholders of medmix Ltd	44.0	9.6	357.4		
Basic earnings per share (in CHF)	1.07	0.28	281.5		
Free cash flow (FCF)	55.6	9.4	493.5		
Net debt as of December 31	110.9	286.0	-61.2		
Employees (number of full-time equivalents) as of December 31	2'036	1'849	10.1		

1) Adjusted for currency effects.

2) Adjusted for acquisition and currency effects.

## Stock market information

	2021
Registered share (in CHF)	
– high	48.44
– low	41.00
– year-end	45.16
Market capitalization as of December 31	
– number of shares issued	41'262'370
– in millions of CHF	1'863
– in percentage of equity	349%
P/E ratio as of December 31	42.2x
Dividend yield as of December 31	1.1%

## Data per share

CHF	2021
Net income attributable to a shareholder of medmix Ltd	1.07
Equity attributable to a shareholder of medmix Ltd	12.90
Ordinary dividend	0.50 <sup>1)</sup>
Payout ratio	47%
Average number of shares outstanding	41'161'439

1) Proposal to the Annual General Meeting.

## Shareholder structure as per December 31, 2021

Number of shares	Number of shareholders	Shareholding
1–100	3'615	0.5%
101–1'000	4'970	4.2%
1'001–10'000	651	4.3%
10'001–100'000	69	5.1%
More than 100'000	19	52.7%
<b>Total registered shareholders and shares (excluding treasury shares medmix Ltd)</b>	<b>9'324</b>	<b>66.8%</b>